RecruitingMale onlyEN originalProstate cancerMetastatic / advanced

A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The goal of this observational study is to compare the number of CTCs enriched by both sampling methods, leukapheresis and collection of peripheral blood in metastatic prostate cancer patients. The main questions it aims to answer are: 1. The advantages and disadvantages of two sampling methods for further diagnosis and treatment; 2. How to obtain further information on the tumour biology of CTC; 3. The mechanisms of prostate cancer invasion and metastasis Participants will have 7.5mL of peripheral blood taken as well as undergo leukapheresis.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Mężczyzna w wieku 18-75 lat
  • Potwierdzenie przerzutów raka - widoczne w badaniach CT, MRI, scyntygrafii kostnej, PET lub biopsji
  • Dobry ogólny stan zdrowia, zdolność do przeprowadzenia zabiegu poboru krwi
  • Prawidłowe wyniki badań krwi, wątroby i nerek
  • Zdolność do zrozumienia i podpisania zgody na badanie

✗ Disqualifies

  • Wcześniejsze leczenie chemioterapią w ciągu ostatnich 5 lat
  • Zły stan ogólny, poważne zaburzenia krążenia, zaburzenia rytmu serca, poważne infekcje
  • Zaburzenia krzepnięcia krwi lub zbyt mało płytek krwi
  • Otrzymywanie osocza krwi w czasie badania

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Maximum age
75 Years
Last updated (source)
August 11, 2026
Sex
Male only

Therapies / drugs in trial

Locations (1)

Renji Hospital, Shanghai Jiao Tong University

Shanghai, China

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/12/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.